{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:51:46Z","timestamp":1792047106652,"version":"4.4.0"},"reference-count":87,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Some of the most common conditions affecting people are kidney diseases. Among them, we distinguish chronic kidney disease and acute kidney injury. Both entities pose serious health risks, so new drugs are still being sought to treat and prevent them. In recent years, such a role has begun to be assigned to sodium-glucose cotransporter-2 (SGLT2) inhibitors. They increase the amount of glucose excreted in the urine. For this reason, they are currently used as a first-line drug in type 2 diabetes mellitus. Due to their demonstrated cardioprotective effect, they are also used in heart failure treatment. As for the renal effects of SGLT2 inhibitors, they reduce intraglomerular pressure and decrease albuminuria. This results in a slower decline in glomelular filtration rate (GFR) in patients with kidney disease. In addition, these drugs have anti-inflammatory and antifibrotic effects. In the following article, we review the evidence for the effectiveness of this group of drugs in kidney disease and their nephroprotective effect. Further research is still needed, but meta-analyses indicate SGLT2 inhibitors\u2019 efficacy in kidney disease, especially the one caused by diabetes. Development of new drugs and clinical trials on specific patient subgroups will further refine their nephroprotective effects.<\/jats:p>","DOI":"10.3390\/ijms25094959","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:33:31Z","timestamp":1714559611000},"page":"4959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["SGLT2 Inhibitors in Kidney Diseases\u2014A Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-2811","authenticated-orcid":false,"given":"Agata","family":"Gajewska","sequence":"first","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-6077","authenticated-orcid":false,"given":"Jakub","family":"Wasiak","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9881-6361","authenticated-orcid":false,"given":"Natalia","family":"Sapeda","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-4746","authenticated-orcid":false,"given":"Ewelina","family":"M\u0142ynarska","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2471\/BLT.17.206441","article-title":"The global burden of kidney disease and the sustainable development goals","volume":"96","author":"Luyckx","year":"2018","journal-title":"Bull. World Health Organ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7861\/clinmed.cg.20.2","article-title":"Chronic kidney disease in adults: Assessment and management","volume":"20","author":"Forbes","year":"2020","journal-title":"Clin. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Turgut, F., Awad, A.S., and Abdel-Rahman, E.M. (2023). Acute Kidney Injury: Medical Causes and Pathogenesis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010375"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2012). Summary of Recommendation Statements. Kidney Int. Suppl., 2, 8\u201312.","DOI":"10.1038\/kisup.2012.7"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gameiro, J., Fonseca, J.A., Outerelo, C., and Lopes, J.A. (2020). Acute Kidney Injury: From Diagnosis to Prevention and Treatment Strategies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061704"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Guzzi, F., Cirillo, L., Roperto, R.M., Romagnani, P., and Lazzeri, E. (2019). Molecular Mechanisms of the Acute Kidney Injury to Chronic Kidney Disease Transition: An Updated View. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194941"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diabetes Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A review","volume":"21","author":"Ehrenkranz","year":"2004","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.bmcl.2011.02.056","article-title":"Discovery of non-glucoside SGLT2 inhibitors","volume":"21","author":"Li","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2042018815575273","article-title":"Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes","volume":"6","author":"Hinnen","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1345\/aph.1Q538","article-title":"Dapagliflozin for the Treatment of Type 2 Diabetes","volume":"46","author":"Anderson","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_13","first-page":"E876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: The statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1080\/07853890.2020.1841281","article-title":"The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection","volume":"53","author":"Brown","year":"2021","journal-title":"Ann. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., and Docimo, G. (2022). An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073651"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2020","journal-title":"Annu. Rev. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00424-020-02361-w","article-title":"Glucose transporters in the kidney in health and disease","volume":"472","author":"Vallon","year":"2020","journal-title":"Pflugers Arch."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/clc.23665","article-title":"Kidney outcomes using a sustained \u226540% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials","volume":"44","author":"Cherney","year":"2021","journal-title":"Clin. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"F587","DOI":"10.1152\/ajprenal.00068.2022","article-title":"Tubuloglomerular feedback: A key player in obesity-associated kidney injury","volume":"322","author":"Liu","year":"2022","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc22-2003","article-title":"Glomerular Hyperfiltration Predicts Kidney Function Decline and Mortality in Type 1 and Type 2 Diabetes: A 21-Year Longitudinal Study","volume":"46","author":"Moriconi","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/dom.15183","article-title":"The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes","volume":"25","author":"Schou","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus","volume":"37","author":"Piperidou","year":"2019","journal-title":"J. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1751-7176.2010.00424.x","article-title":"Identification and Management of Albuminuria in the Primary Care Setting","volume":"13","author":"Kuritzky","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s42255-020-0204-y","article-title":"A molecular mechanism explaining albuminuria in kidney disease","volume":"2","author":"Butt","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Klen, J., and Dol\u017ean, V. (2023). SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071995"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.12659\/MSM.903660","article-title":"Albuminuria and Endothelial Dysfunction in Patients with Non-Diabetic Chronic Kidney Disease","volume":"23","author":"Huang","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rapa, S.F., Di Iorio, B.R., Campiglia, P., Heidland, A., and Marzocco, S. (2020). Inflammation and Oxidative Stress in Chronic Kidney Disease\u2014Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010263"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gohari, S., Ismail-Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., and Gohari, S. (2023). The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: A systematic review and meta-analysis of randomized controlled trials. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01512-1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1205834","DOI":"10.3389\/fimmu.2023.1205834","article-title":"Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger, E., Mihaljevi\u0107, V., Steiner, K., \u0160ari\u0107, S., Kurevija, T., Majnari\u0107, L.T., \u0106ur\u010di\u0107, I.B., and Canecki-Var\u017ei\u0107, S. (2023). Immunomodulatory Effects of SGLT2 Inhibitors\u2014Targeting Inflammation and Oxidative Stress in Aging. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20176671"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: From mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00592-021-01681-2","article-title":"Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy","volume":"58","author":"Castoldi","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102934","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review","volume":"8","year":"2021","journal-title":"Front. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"897167","DOI":"10.3389\/fphar.2022.897167","article-title":"SGLT2 inhibitors suppress epithelial\u2013mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R\/PI3K pathway","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5152\/eurasianjmed.2018.17397","article-title":"Reactive Oxygen Species: The Dual Role in Physiological and Pathological Conditions of the Human Body","volume":"50","author":"Bardaweel","year":"2018","journal-title":"Eurasian J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Llorens-Cebri\u00e0, C., Bosch, M.M.-V.D., Vergara, A., Jacobs-Cach\u00e1, C., and Soler, M.J. (2022). Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules, 12.","DOI":"10.3390\/biom12010143"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tsai, K.-F., Chen, Y.-L., Chiou, T.T.-Y., Chu, T.-H., Li, L.-C., Ng, H.-Y., Lee, W.-C., and Lee, C.-T. (2021). Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants, 10.","DOI":"10.3390\/antiox10081166"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Tai, S., Zhang, N., Fu, L., and Wang, Y. (2023). Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115213"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.2147\/DMSO.S336791","article-title":"The Factors Influencing the Renal Glucose Threshold in Patients with Newly Diagnosed Type 2 Diabetes Mellitus","volume":"14","author":"Cui","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12244","article-title":"Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport","volume":"276","author":"DeFronzo","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Saisho, Y. (2020). SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?. Diseases, 8.","DOI":"10.3390\/diseases8020014"},{"key":"ref_50","first-page":"216","article-title":"Weight Loss Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients with Obesity without Diabetes: A Systematic Review","volume":"18","author":"Pratama","year":"2022","journal-title":"Acta Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","article-title":"SGLT2 Inhibitors and Safety in Older Patients","volume":"18","author":"Pollack","year":"2022","journal-title":"Heart Fail. Clin."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S125\u2013S143.","DOI":"10.2337\/dc22-S009"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: Are they safe?","volume":"130","author":"Filippatos","year":"2018","journal-title":"Postgrad. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1045235","DOI":"10.3389\/fphar.2022.1045235","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"C309","DOI":"10.1093\/eurheartjsupp\/suad055","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: An updated evidence-based practical guidance for clinicians","volume":"25","author":"Monzo","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"ref_62","first-page":"523","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev. Espa\u00f1ola De Cardiol. (Engl. Ed.)"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2021). Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26237213"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/HYPERTENSIONAHA.123.20598","article-title":"Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart","volume":"80","author":"Santulli","year":"2023","journal-title":"Hypertension"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sawaf, H., Thomas, G., Taliercio, J.J., Nakhoul, G., Vachharajani, T.J., and Mehdi, A. (2022). Therapeutic Advances in Diabetic Nephropathy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11020378"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e030552","DOI":"10.1161\/JAHA.123.030552","article-title":"Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real-World Observation Using a Nationwide, Population-Based Cohort","volume":"13","author":"Lim","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Singh, P., Goyal, L., Mallick, D.C., Surani, S.R., and Yashi, K. (2023). Role of Sodium-Glucose Co-Transporter 2 Inhibitors in Chronic Kidney Disease, Congestive Heart Failure and Stroke\u2014A Review and Clinical Guide for Healthcare Professionals. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196202"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","article-title":"Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction","volume":"5","author":"McAlister","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 Inhibitors and the Diabetic Kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Cianciolo, G., De Pascalis, A., Gasperoni, L., Tondolo, F., Zappulo, F., Capelli, I., Cappuccilli, M., and La Manna, G. (2020). The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i. Molecules, 25.","DOI":"10.3390\/molecules25122757"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: A meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"973129","DOI":"10.3389\/fcvm.2022.973129","article-title":"Risk of hypovolemia associated with sodium\u2013glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials","volume":"9","author":"Rong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_86","first-page":"e99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Tanr\u0131verdi, M., Ba\u015ftemir, M., Demirbakan, H., \u00dcnalan, A., T\u00fcrkmen, M., and Tanr\u0131verdi, G. (2023). Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01464-6"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:25Z","timestamp":1760107105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":87,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094959"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094959","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}